Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
复制标题
DOI：
10.1016/j.antiviral.2021.105158
复制
发表时间：
2021-10
影响因子：
7.6
通讯作者：
中科院分区：
文献类型：
--
作者：
自从神经氨酸酶抑制剂奥司他韦和扎那米韦被批准用于治疗和预防流感以来，已经有20多年了。全球监测指南和评估耐药性的方法最初是由神经氨酸酶抑制物敏感性网络(NISN)制定的，该网络于10年前与国际流感和其他呼吸道病毒疾病学会(ISIRV)合并，成为国际流感和其他呼吸道病毒疾病抗病毒小组(ISIRV-AVG)。随着新的流感聚合酶抑制剂的不断开发和最近巴洛沙韦的批准，isirv-AVG在2019年8月举行了一次闭门会议，讨论对这些抑制剂的耐药性的影响。根据这次会议和对当前文献的回顾，本文旨在总结目前关于聚合酶抑制剂耐药性的临床影响的知识，以及在体外和动物模型中监测和实验室评估耐药性的途径和方法。我们强调了当前知识中的局限性和差距，并提出了解决这些差距的一些策略，包括需要对流感抗病毒药物组合进行更多的临床研究。从流感耐药性监测中吸取的经验教训也可能有助于建立未来对SARS-CoV-2的药物敏感性监测和测试。
It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Following this meeting and review of the current literature, this article is intended to summarize current knowledge regarding the clinical impact of resistance to polymerase inhibitors and approaches for surveillance and methods for laboratory evaluation of resistance, both in vitro and in animal models. We highlight limitations and gaps in current knowledge and suggest some strategies for addressing these gaps, including the need for additional clinical studies of influenza antiviral drug combinations. Lessons learned from influenza resistance monitoring may also be helpful for establishing future drug susceptibility surveillance and testing for SARS-CoV-2.
登录
查看更多内容
影响因子：
7.6
作者：
Abed, Yacine;Fage, Clement;Boivin, Guy
通讯作者：
Boivin, Guy
影响因子：
6.4
作者：
Checkmahomed, Liva;M'hamdi, Zeineb;Boivin, Guy
通讯作者：
Boivin, Guy
影响因子：
6.4
作者：
Chan, Paul K. S.;Lee, Nelson;Dreyer, Nancy A.
通讯作者：
Dreyer, Nancy A.
影响因子：
6.4
作者：
Deyde, Varough M.;Xu, Xiyan;Klimov, Alexander I.
通讯作者：
Klimov, Alexander I.
影响因子：
7.6
作者：
Beigel, John H.;Nam, Hannah H.;Sims, Amy C.
通讯作者：
Sims, Amy C.